The trajectory of Viagra presents a interesting case for observers in the drug sector. While initially a tremendous success, creating vast sums, the patent lapse and the subsequent flood of off-brand competitors have considerably changed earnings. This poses questions about the ongoing profitability of analogous medication projects and suggests tha